Keele Research Repository

Yu, D ORCID: https://orcid.org/0000-0002-8449-7725 (2020) Co-prescription of gabapentinoids and opioids among adults with and without osteoarthritis in the United Kingdom between 1995 and 2017. Rheumatology, 60 (4). pp. 1942-1950.

	Text coprescription paperRheumatology fianl clean copy.docx - Accepted Version Restricted to Repository staff only until 7 November 2021. Download (111kB)
	Text Online Supplemental File 1 final clean copy.docx - Supplemental Material Restricted to Repository staff only until 7 November 2021. Download (125kB)

Abstract

Objectives
To produce national and regional estimates and trends of gabapentinoid-opioid co-prescribing rates in patients with osteoarthritis, both in absolute terms and relative to matched controls without osteoarthritis.

Methods
Using the UK Clinical Practice Research Datalink database we first constructed age-sex-practice-date 1:1 matched cohorts of patients aged ≥40 years with and without a new diagnosis of osteoarthritis between 1995-2017 and estimated the relative incidence of first gabapentinoid prescription. Incident gabapentinoid users in both cohorts were followed to estimate and compare the event-rate of gabapentinoid-opioid co-prescription (prescription from both classes within the same 28-day window).

Results
The incidence of first gabapentinoid prescription was 3-fold higher in patients with osteoarthritis than in matched controls (n=215,357; incidence rate ratio (IRR) 2.93; 95%CI: 2.87-3.00). Among incident gabapentinoid users with osteoarthritis (n=27,374, median follow-up 3.9 years) the event-rate of gabapentinoid-opioid co-prescription was 4.03 (4.02-4.05) per person-year. The rate was higher in osteoarthritis patients classed as long-term gabapentinoid users (6.24; 6.22-6.26). These rates were significantly higher than incident gabapentinoid users without osteoarthritis (adjusted-IRR: 1.29 (1.28-1.30)). This elevated risk was observed across age, sex, geographic-regions, and calendar-years, when restricted to strong-opioids and to long-term gabapentinoid users, and when co-prescription was defined as within 14-days and same-day prescribing.

Conclusions
Patients with osteoarthritis not only have a higher risk of being prescribed a gabapentinoid but, once prescribed a gabapentinoid, are also at greater risk of opioid co-prescription. Strict restriction of gabapentinoid-opioid co-prescription, and improved access to, and uptake of, effective non-pharmacological and surgical alternatives for osteoarthritis are required.

Item Type:	Article
Uncontrolled Keywords:	gabapentinoid, opioid, gabapentinoid-opioid co-prescription, osteoarthritis
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC925 Diseases of the musculoskeletal system
Divisions:	Faculty of Medicine and Health Sciences > School of Primary, Community and Social Care
Depositing User:	Symplectic
Date Deposited:	05 Oct 2020 13:46
Last Modified:	13 Apr 2021 14:40
URI:	https://eprints.keele.ac.uk/id/eprint/8729

Actions (login required)

View Item